Hidden Cell-to-Cell Messaging Networks Drive Triple-Negative Breast Cancer Resistance

Triple-negative breast cancer has long been one of the most feared diagnoses in oncology. Lacking the three molecular targets that define most other breast cancers—the estrogen receptor, the progesterone receptor, and HER2—it offers clinicians few options beyond chemotherapy and, more recently, immunotherapy. Yet even among patients with apparently identical tumors, outcomes diverge dramatically. Some respond well to initial treatment; others relapse within months, their disease having already spread to distant organs. A new review published in the Journal of Translational Medicine argues that the answer to this stubborn variability may not lie primarily inside the cancer cells themselves, but in the dense web of chemical conversations they conduct with their surroundings.

The review, authored by Lingling Mei, Zhihua Feng, Lizhu Chen, Weiwei Huang, and Yangkun Shen, with contributions from researchers at Fujian Normal University, Fuzhou Hospital of Traditional Chinese Medicine, and Fujian Cancer Hospital, proposes a unifying framework it calls paracrine network-driven niche evolution. Paracrine signaling is the process by which cells release molecules that act on nearby neighbors rather than traveling through the bloodstream to distant targets. In a tumor, this local messaging system links malignant cells to immune cells, fibroblasts, endothelial cells lining blood vessels, and other stromal residents. The authors contend that the hallmark features of triple-negative breast cancer—its heterogeneity, its early metastasis, and its frequent resistance to therapy—are emergent properties of these networks rather than fixed traits of individual tumor cells.

What makes this framework timely is the arrival of single-cell and spatial omics technologies. Traditional bulk sequencing averages out the identities of thousands of cells, obscuring the fact that a tumor is not a uniform mass but a patchwork of spatially organized neighborhoods. Single-cell RNA sequencing can now profile gene expression in individual cells, while spatial transcriptomics maps where those cells sit relative to one another. Applied to triple-negative breast cancer, these tools reveal that tumors are organized into distinct cellular niches, each maintained by its own repertoire of signaling molecules. Cancer cells at the invasive edge may be bathed in different signals than those near necrotic cores, and each niche can harbor cells with distinct vulnerabilities and distinct capacities for survival under treatment pressure.

Two principal communication modalities sustain these niches. The first is the release of soluble factors: cytokines, chemokines, growth factors, and metabolites that diffuse through the extracellular space and bind receptors on neighboring cells. The second is the exchange of extracellular vesicles, tiny membrane-bound packages that carry proteins, lipids, and nucleic acids from one cell to another. Unlike soluble factors, vesicles can deliver a coordinated cargo—microRNAs, messenger RNAs, and signaling proteins in a single package—effectively reprogramming the recipient cell. The review emphasizes that these two modes are not independent; they reinforce one another in feedback loops that can amplify a signaling state once it is established, locking parts of the tumor into aggressive behavioral patterns.

One of the most consequential ideas in the review is that therapy itself reshapes these communication networks. Chemotherapy is designed to kill dividing cells, but it also triggers stressed tumor cells and stromal cells to release new cocktails of signals. Damaged cells may secrete damage-associated molecular patterns that summon and polarize immune cells, sometimes in ways that blunt the immune response rather than enhance it. Surviving tumor cells may upregulate survival pathways in response to signals from cancer-associated fibroblasts. The result is therapy-induced rewiring: the paracrine network that existed before treatment is not the same network that exists after it. This dynamic remodeling helps explain why resistance so often emerges not through a single mutation but through a coordinated shift in the tumor’s social environment, and why the microenvironment can retain a kind of memory of prior treatment, priming it for faster adaptation upon relapse.

The consequences of this rewiring extend across every axis of tumor behavior. Tumor-cell plasticity—the capacity of cancer cells to switch states, for example from epithelial to mesenchymal-like phenotypes—is promoted by paracrine cues from the niche, endowing cells with motility and survival traits that support metastatic competence. Immune dysfunction is likewise a network phenomenon: signals such as certain chemokines recruit immunosuppressive myeloid cells and regulatory T cells into the tumor, while others exclude cytotoxic lymphocytes from critical regions, undermining both natural immune surveillance and immunotherapies such as immune checkpoint inhibitors. Vascular and metabolic remodeling, too, are driven by local signaling, as tumor cells and stromal cells induce abnormal vessel growth and reshape nutrient and oxygen availability, creating gradients that further diversify the niches within a single tumor.

Crucially, the review does not stop at diagnosis of the problem; it surveys therapeutic strategies aimed at interrupting pathological communication. These include blocking cytokine and chemokine signaling pathways, targeting stromal cells such as cancer-associated fibroblasts that nurture tumor cells, normalizing tumor vasculature to improve drug delivery and oxygenation, and intercepting extracellular vesicles or their cargo before they can reprogram recipient cells. The authors also discuss approaches that combine these interventions with existing chemotherapy and immunotherapy, on the logic that dismantling a tumor’s communication infrastructure may render the remaining cancer cells more vulnerable to conventional agents. Each strategy, however, depends on identifying which communication dependencies dominate in a given patient’s tumor—a task that requires better biomarkers and functional validation than currently exist.

Indeed, the review is candid about the obstacles standing between this framework and the clinic. Many paracrine pathways are redundant: blocking one signal may simply redirect traffic through another. Some communication molecules play protective roles in healthy tissue, raising the specter of toxicity when they are systemically inhibited. Extracellular vesicles are technically challenging to characterize and track in patients, complicating both biomarker development and drug targeting. Functional validation—demonstrating in rigorous models that a given network dependency is truly required for tumor survival—remains uneven across the field. The authors argue that overcoming these challenges will require integrating spatially resolved molecular data with functional assays and carefully designed clinical trials, so that combination therapies can be guided by biomarkers that reveal which communication circuits a tumor actually depends upon.

The conceptual shift the review advocates is subtle but potentially transformative. For decades, cancer research has focused on cell-intrinsic events: mutations, copy-number changes, and epigenetic alterations within the tumor cell. Those remain important, but the paracrine network framework insists that they are only half the story. Progression and treatment failure, in this view, are emergent consequences of spatially organized and temporally rewired signaling communities—properties that cannot be predicted by sequencing the cancer genome alone. If the framework holds up under experimental scrutiny, it points toward a future in which a patient’s tumor is mapped not just for its mutations but for its communication architecture, and therapy is designed to collapse the specific signaling dependencies that keep that architecture alive. For a disease as heterogeneous and relentless as triple-negative breast cancer, targeting the conversation rather than only the cells having it may prove to be the strategic breakthrough that has so far remained out of reach.

Subject of Research: Paracrine signaling networks in the tumor microenvironment of triple-negative breast cancer

Article Title: Paracrine networks driving heterogeneity and therapy resistance in triple-negative breast cancer

Article References: Paracrine networks driving heterogeneity and therapy resistance in triple-negative breast cancer. (n.d.). https://doi.org/10.1186/s12967-026-09077-y

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09077-y

Keywords: triple-negative breast cancer, tumor microenvironment, paracrine signaling, extracellular vesicles, cytokines, chemokines, cancer-associated fibroblasts, therapy resistance, tumor heterogeneity, single-cell omics, spatial transcriptomics, immunotherapy